NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Enrolling By InvitationPhase 1

Sponsor: USWM CT, LLC

Conditions: Neoplasms

Interventions: ADP adoptive cell therapy

Countries: United States, Australia, Canada, Germany, Italy, Netherlands, Spain, United Kingdom

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants who have received at least one dose of ADP adoptive cell therapy agent.
* Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
* Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* The investigator is responsible for review of medical history.
* Capable of giving signed informed consent.

Exclusion Criteria:

\- None

Locations (24)

Atlanta, Georgia, United States
Baltimore, Maryland, United States
Bethesda, Maryland, United States
Ann Arbor, Michigan, United States
St Louis, Missouri, United States
New York, New York, United States
Durham, North Carolina, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Dallas, Texas, United States
Houston, Texas, United States
Milwaukee, Wisconsin, United States
Melbourne, Victoria, Australia
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Munich, Bavaria, Germany
Cologne, North Rhine-Westphalia, Germany
Milan, Lombardy, Italy
Amsterdam, Netherlands
Seville, Spain
London, United Kingdom
Manchester, United Kingdom
Sutton, United Kingdom